Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT03398148 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03398148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03398148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
AbbVie
Phase
Phase 2/3
Overall status
Completed
Start date
March 7, 2018
Completion date
May 11, 2023
Enrollment
1,558 (actual)
Sites
430

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)